Int. Journal of Clinical Pharmacology and Therapeutics, Volume 51 - October (807 - 815)

Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies
Hiroko Hachiken1, Ai Murai1, Kyoichi Wada2, Takeshi Kuwahara2, Kouichi Hosomi1, Mitsutaka Takada1
1 Division of Clinical Drug Informatics, School of Pharmacy, Kinki University, and 2 Department of Pharmacy, National Cerebral and Cardiovascular Center, Osaka, Japan

Add to Cart  

 

DOI 10.5414/CP201914

Abstract

Objective: To provide further insights on the risks of gastrointestinal (GI) complications in individuals using low-dose aspirin (LDA), we investigated the concomitant use of LDA and antisecretory drugs. Additionally, we examined the frequency distributions of prescribing sequences for LDA and antisecretory drugs. Methods: Data from a computerized prescription order entry system was analyzed at the National Cerebral and Cardiovascular Center of Japan. LDA use in combination with H2-receptor antagonists (H2RAs) and proton pomp inhibitors (PPIs) was examined over the period from January 2001 to December 2010. Prescription sequence symmetry analyses were used to identify LDA-induced H2RAs or PPIs users. Results: In December 2010, PPIs accounted for 9.9% of the prescriptions for buffered LDA users and 16.1% of those for enteric-coated LDA users. Incident use of PPIs occurred more frequently among enteric-coated LDA users than buffered LDA users (17.6% vs. 11.0%, respectively). Prescription sequence symmetry analyses of PPI use revealed significant associations with enteric-coated LDA use, resulting in adjusted sequence ratios of 1.82 (95%CI, 1.11 – 3.03) and 1.87 (95% CI, 1.26 – 2.83) at intervals of 182 and 365 days, respectively. Enteric-coated LDA users tended to initiate PPI therapy on the same date more frequently than buffered LDA users (35.1% vs. 10.8%, respectively). Conclusions: Our findings do not support the notion that entericcoated LDA products confer a lower risk for GI complications than buffered formulations, but may conversely imply that the risk of GI complications associated with buffered LDA is lower than that of enteric-coated LDA.

Author Details

Authors

Departments

  • 1 Division of Clinical Drug Informatics, School of Pharmacy, Kinki University, and
  • 2 Department of Pharmacy, National Cerebral and Cardiovascular Center, Osaka, Japan

Address

Mitsutaka Takada, PhD
Division of Clinical Drug Informatics
School of Pharmacy, Kinki University
577-8502, 3-4-1, Kowakae,
Higashi-osaka, Osaka, 577-8502, Japan
Email: [email protected]

Log in for Subscribers

Citation

Hiroko Hachiken, Ai Murai, Kyoichi Wada, Takeshi Kuwahara, Kouichi Hosomi and Mitsutaka Takada.Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies. 2013; 51: 807-815. doi: 10.5414/CP201914.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart